With steadily improved cure rates for children with newly diagnosed acute lymphoblastic
leukaemia (ALL), treating relapsed ALL has become increasingly challenging largely due to …

The outcome for children with acute lymphoblastic leukemia (ALL) has improved dramatically
with current therapy resulting in an event free survival exceeding 75% for most patients. …

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, accounting
for 25% of all childhood cancers. In the United States, approximately 3000 children aged 1 …

… /m 2 /d and a stepwise dosage of 15/30 µg/m 2 /d (15 µg/m 2 /d for the first 7 days and 30
µg/m 2 /d thereafter). After determining the recommended dosage (stepwise 5/15 µg/m 2 /d), we …

We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials
(Total Therapy Studies 11, 12, 13A, 13B, and 14) between 1984 and 1999. The event-free …

… of 14 d) before metabolite measurements and then correlated with NUDT15 diplotype (as
normal, intermediate or low NUDT15 activity) using a linear regression model (two-sided) (c,d). …

Purpose Methotrexate (MTX) can cause significant clinical neurotoxicity and asymptomatic
leukoencephalopathy. We sought to identify clinical, pharmacokinetic, and genetic risk factors …

Somatic alterations of the lymphoid transcription factor gene PAX5 (also known as BSAP) are
a hallmark of B cell precursor acute lymphoblastic leukemia (B-ALL) 1 , 2 , 3 , but inherited …

To resolve the genetic heterogeneity within pediatric high-risk B-precursor acute lymphoblastic
leukemia (ALL), a clinically defined poor-risk group with few known recurring cytogenetic …

… (b,d) Early treatment response measured by MRD at the end of induction was also related
to genotype at rs3824662 in both the COG P9906 (b) and COG P9905 (d) cohorts, with P …